USFDA completes Cipla unit inspection with no Form 483 observations

Regulatory & Legal View source PDF Explain this filing

CIPLA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.5%Reaction day

₹1330.90

prior close

₹1332.40

announcement price

After-mkt

timing

Nifty 100market-0.7%+1.3% vs market

Pharmaceuticals peers, median of 170sector-1.6%+2.1% vs sector

On the reaction day the stock moved 1.3 pts more than Nifty 100 and 2.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

-0.0

15m

+0.0

30m

-0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.5-0.7+1.3-1.6+2.1

Next day

+1.2-0.0+1.2-0.5+1.7

+1.4+0.2+1.2+1.5-0.1

+2.6+0.0+2.6+2.5+0.1

+2.0+1.1+0.9+2.7-0.7

+3.6pendingpending+1.5+2.1

—————

15d

—————

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 170Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The USFDA conducted a routine manufacturing standards inspection at InvaGen Pharmaceuticals, Cipla's wholly owned unit in Hauppauge, New York, from October 19 to 22, 2026. The inspection ended with zero Form 483 observations.

Likely market impact

A positive compliance outcome that reduces regulatory concern at the facility, with no inspection observations reported.